Abstract
Objective The aim of this study was to evaluate the cost effectiveness of a mobile-based intervention for patients with type 2 diabetes mellitus (T2DM) and compare it with the usual management mode. Method A total of 215 patients with T2DM in a tertiary-care hospital specific to diabetes were selected as the study population. This study was conducted from January 1, 2019 to January 1, 2020. Of the 215 patients, 130 were randomly assigned to the mHealth group and 85 were assigned to the usual care group. IBM SPSS 25.0 software was used for descriptive statistics, t tests, chi-square tests, and correlation analyses. Haemoglobin A1c (HbA1c) was the effectiveness parameter adopted. Cost-effectiveness analyses were performed, and incremental cost-effectiveness ratios (ICERs) were calculated. Results Of the 215 patients with T2DM, the proportion of male patients was 66.0%. The mean age of the patients was 47.2 (SD 9.95). Differences in baseline information were not statistically significant between the two groups (P > 0.05). At the 3-, 6-, and 12-month follow-ups, the mHealth group reported higher control rates of HbA1c than the usual care group, 67.9% versus 46.2% (P < 0.001), 72.4% versus 45.4% (P < 0.001), and 74.6% versus 47.1% (P < 0.001), respectively. The value of HbA1c was positively related to total patient cost, material fee, Western medicine fee, and hospitalization expenses (P < 0.05), with correlation coefficients of 0.202, 0.200, 0.172, and 0.183, respectively. The costs of the mHealth group and usual care group were CNY¥ 1169.76 and CNY¥ 1775.44 per patient/year, respectively. The incremental cost of the mHealth intervention was CNY¥ −605.68 per patient/year. The ICER was CNY¥ −22.02 per patient/year. Conclusion Compared with the usual care mode, the mHealth management model for patients with T2DM improved the control rate of HbA1c, and the mHealth management mode had better cost effectiveness.
Highlights
With the development of the social economy, the number of patients with diabetes mellitus (DM) in the world is increasing
2.49 billion disability-adjusted life years were lost in 2010, of which 47 million were lost due to DM [3]. e Total Economic Burden of Chronic Noncommunicable Diseases in China study showed that the total economic burden of International Journal of Endocrinology
Subjects. is study was conducted in a tertiary-care hospital specific to diabetes in Tianjin, China, from January 1, 2019, to January 1, 2020. e study included patients of both sexes aged 18 years and above with type 2 diabetes mellitus (T2DM) registered in the clinical database for enrolment and follow-up of patients with DM living in the territories served by Community Health Care
Summary
With the development of the social economy, the number of patients with diabetes mellitus (DM) in the world is increasing. According to estimates by the World Health Organization, as of November 2016, the number of adults with DM worldwide had increased to 422 million [1]. During the past 30 years, the prevalence of DM in China has been severe. According to an epidemiological survey conducted by the National Health and Family Planning Commission, there are approximately 3,000 new cases of DM in China every day, an increase of approximately 200,000 patients every year [2]. A large population base, high prevalence, and high incidence of complications impose a heavy economic burden on patients, their families, and society. 2.49 billion disability-adjusted life years were lost in 2010, of which 47 million (or 1.9%) were lost due to DM [3]. e Total Economic Burden of Chronic Noncommunicable Diseases in China study showed that the total economic burden of International Journal of Endocrinology
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
